Studying insurance for skin cancer treatment
Part of Cancer, Skin clinical trials.
This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of skin cancer: Merkel cell carcinoma, mucosal melanoma, basal cell carcinoma, or another rare skin cancer such as squamous cell.
- Your cancer is at a stage that can be operated on (stage II, III, or IV) or might become operable after treatment.
- You are 18 years old or older.
- A surgeon has described a plan to remove your cancer with surgery.
- Your doctor plans to give you immunotherapy (drugs like nivolumab, ipilimumab, or pembrolizumab) before surgery.
- You have not had immunotherapy, chemotherapy, or radiation for this cancer in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.
This trial tests a combination of two immunotherapy drugs, nivolumab and relatlimab, before surgery for Merkel cell carcinoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial is testing a lab method to see if a specific type of immunotherapy can work against Merkel cell carcinoma. It may help find new treatment options for people with this skin cancer.
This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.
This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.
This study tests a personalized cell therapy called TIL (tumor-infiltrating lymphocytes) for people with advanced skin cancers that have not responded to immunotherapy. Doctors take your tumor cells, grow immune cells from them, and then infuse them back to fight the cancer.
Hear when a new Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.